Growth and human milk intake outcomes from postdischarge feedings among very-low-birth-weight preterm infants: A systematic review.

Nutr Clin PractApr 29, 2026 (epub)
Clinical ResearchPediatricsGastroenterology

Tara Rebele, Allison Gomes, Melanie Newkirk et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the effects of postdischarge fortified human milk (HM) or breastfeeding with formula on growth and HM intake in very-low-birth-weight preterm infants. Analyzing four studies with 548 infants, it was found that fortified feeding strategies led to significantly greater weight gain and head circumference at 6 months corrected age compared to unfortified feeding.

Key findings

  • Fortified feeding groups showed significantly greater weight gain at 6 months corrected age.
  • One study reported significantly greater head circumference in fortified groups at 6 months corrected age.
  • Three studies indicated comparable or greater HM intake in fortified feeding groups.

Why it matters

Understanding the impact of different feeding strategies on growth outcomes in preterm infants is crucial for optimizing postdischarge care and ensuring adequate nutrition during a vulnerable period of development.

Source

PubMed · PMID 42051106

Published in Nutr Clin Pract. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.